MedTrace Logo

Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

NCT03854344 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.

Conditions

  • Pain, Postoperative
  • Burns

Interventions

DRUG

Lidocaine Hydrochloride

Injected subcutaneously for skin graft harvesting

DRUG

Liposomal bupivacaine

Injected subcutaneously for skin graft harvesting

DRUG

Bupivacaine Hydrochloride

Used for regional nerve block for skin graft harvesting

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2025-08-06
Completion
2025-10-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03854344 on ClinicalTrials.gov